WORLD INTELLECTUAL PROPERTY ORGANIZATION International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6:

A3

(11) International Publication Number:

WO 96/21028

C12N 15/62, C07K 14/725, 16/28, G01N G01N 33/68, A61K 38/17, C07K 19/00

(43) International Publication Date:

11 July 1996 (11.07.96)

(21) International Application Number:

PCT/US95/16937

(22) International Filing Date:

28 December 1995 (28.12.95)

(81) Designated States: CA, JP, MX, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT,

(30) Priority Data:

08/367,589

3 January 1995 (03.01.95)

US

(71) Applicant: PROCEPT, INC. [US/US]; 840 Memorial Drive,

Cambridge, MA 02139 (US).

(72) Inventors: BANERJI, Julian; 37 Lincoln Street, Lincoln, MA 01773 (US). KHANDEKAR, Sanjay; 72 Grassland Street, Lexington, MA 02173 (US). BRAUER, Pamela; 21 Gedney Court, Salem, MA 01970 (US). NAYLOR, Jerome: 99 Marion Street, Somerville, MA 02143 (US). MCKEEVER, Una; 36 Robinwood Avenue #1, Boston, MA 02130 (US). JESSON, Michael; 19 Plain Street, Hopedale, MA 01747 (US). JONES, Barry; 341 Gurney Street, Cambridge, MA 02138 (US).

(74) Agents: CARROLL, Alice, O. et al.; Hamilton, Brook, Smith & Reynolds, Two Militia Drive, Lexington, MA 02173 (US).

Published

With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

(88) Date of publication of the international search report: 12 September 1996 (12.09.96)

(54) Title: SOLUBLE HETERODIMERIC T CELL RECEPTORS AND THEIR ANTIBODIES

(57) Abstract

Heterodimeric T cell receptor proteins, comprising α and β subunits joined by at least one disulfide bond, are disclosed. The α and β subunits are generated as chimeric polypeptides, utilizing ζ chains or constant regions of IgG1 as chimeric partners. Also disclosed are soluble heterodimeric T cell recpetor molecules with a conformation essentially indistinguishable from that appearing on the surface of T cells. The invention also concerns DNA encoding the heterodimeric TCR, transfer vectors comprising DNA encoding the heterodimeric TCR, and host cells containing such transfer vectors. In addition, the invention pertains to various uses of heterodimeric TCR. The proteins can be used in molecular assays designed to measure their binding to ligands, including MHC/HLA-peptide antigen complexes or TCRspecific antibodies. Such assays are useful for the detection of agents that block the TCR-ligand interaction. The heterodimeric TCR can also be used to immunize animals, including humans, to produce TCR-specific antibodies. In addition, either in their native or denatured conformation, the proteins can be used to vaccinate animals, including humans, in order to suppress the immune response of T cells bearing TCR that share antigenic epitopes with the vaccinating protein.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
ΑU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JР	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgystan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic	SD	Sudan
CF	Central African Republic		of Korea	SE	Sweden
CG	Congo	KR	Republic of Korea	SG	Singapore
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	u	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LR	Liberia	SZ	Swaziland
CS	Czechoslovakia	LT	Lithuania	TD	Chad
CZ	Czech Republic	LU	Luxembourg	TG	Togo
DE	Germany	LV	Latvia	TJ	Tajikistan
DK	Denmark	MC	Monaco	Ϋ́T	Trinidad and Tobago
EE	Estonia	MD	Republic of Moldova	ÜA	Ukraine
ES	Spain	MG	Madagascar	UG	Uganda
FI	Finland	ML	Mali	US	United States of Americ
FR	France	MN	Mongolia	UZ	Uzhekistan
GA	Gabon	MR	Mauritania	VN	Viet Nam

Inter anal Application No PCI/US 95/16937

A. CLASSIFICATION OF SUBJECT MATTER IPC 6 C12N15/62 C07K14/725 C07K16/28 G01N33/68 A61K38/17 C07K19/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols) IPC 6 $C07\,K$

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
		
X	WO,A,94 12648 (INST NAT SANTE RECH MED	1,2,
	;IMMUNOTECH SA (FR); BONNEVILLE MARC (FR))	9-11,18,
	9 June 1994	20-38
Υ	see the whole document	1-3,5,6,
		8-12,14,
		15,17-38
		1.0
X	PROCEEDINGS OF THE NATIONAL ACADEMY OF	1,2,
	SCIENCES OF USA,	9-11,18,
	vol. 91, August 1994, WASHINGTON US,	20,21, 24-27
	pages 8462-8466, XP002008360	24-27
	J. KAPPLER ET AL: "Binding of a soluble	
	alpha-beta T-cell receptor to	
	superantigen/major histocompatibility	
v	complex ligands" see the whole document	22,23,
T	see the whole document	28-38
		20-30
	-/	1
	-/	

Further documents are listed in the continuation of box C.	Patent family members are listed in annex.
Special categories of cited documents: A document defining the general state of the art which is not considered to be of particular relevance. E* earlier document but published on or after the international filling date. L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified). O* document referring to an oral disclosure, use, exhibition or other means. P* document published prior to the international filling date but later than the priority date claimed.	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. "&" document member of the same patent family
Date of the actual completion of the international search 15 July 1996	Date of mailing of the international search report 2 3, 07, 96
Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentiaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo ni, Fax: (+31-70) 340-3016	Authonzed officer Van der Schaal, C

Inter onal Application No PCI/US 95/16937

_		PC1/03 95/1693/
	ADON; DOCUMENTS CONSIDERED TO BE RELEVANT	
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	SCIENCE, vol. 256, 29 May 1992, pages 1318-1321, XP002008361 I. ENGEL ET AL: "High-efficiency expression and solubilization of functional T cell antigen receptor heterodimers"	1-4,6,7, 9-13,15, 16,18-21
Υ	see the whole document	22-38
X Y	WO,A,92 01715 (UNIV LELAND STANFORD JUNIOR) 6 February 1992 see the whole document	1-3,6, 9-12,15, 18-21 22,23,
1	see the whole document	29-38
X	PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA 91 (24). 1994. 11408-11412. ISSN: 0027-8424, XP002008362 CHANG H-C ET AL: "A general method for facilitating heterodimeric pairing between two proteins: Application to expression of alpha and beta T - cell receptor	1-3,6, 9-12,15, 18-21
Υ	extracellular segments."	22,23, 29-38
X	PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, vol. 91, December 1994, WASHINGTON US, pages 12862-12866, XP002008363 K. MATSUI ET AL: "Kinetics of T-cell receptor binding to peptide/I-Ek complexes"	1,2, 9-11, 18-21, 24,25
Y	see the whole document	22,23, 26-38
X	NATURE, vol. 356, 30 April 1992, pages 793-796, XP002008364 S. WEBER ET AL: "Specific low-affinity recognition of major histocompatibility complex plus peptide by soluble T-cell receptor" cited in the application	1-3,5,6, 8-12,14, 15, 17-21, 24,25
Y	see the whole document	22,23, 26-38
	-/	

Inter onal Application No PC I/US 95/16937

		PC1/US 95/16937
Continu	DOCUMENTS CONSIDERED TO BE RELEVANT	
ategory *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, vol. 89, August 1992, WASHINGTON US, pages 6871-6875, XP002008365 D. EILAT ET AL: "Secretion of a soluble, chimeric gamma-delta T-cell receptor-immunoglobulin heterodimer" see the whole document	1-3,5,6, 8-12,14, 15,17-38
Y	JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 268, no. 21, 25 July 1993, MD US, pages 15455-15460, XP002008366 F.DAVODEAU ET AL: "Secretion of disulfide-linked human T-cell receptor gamma-delta heterodimers" see the whole document	1,2, 9-11, 18-38
Y	WO,A,93 12814 (IMMUNE RESPONSE CORP INC) 8 July 1993 see the whole document	22,23, 29-38
P , X	IMMUNOLOGIST (1995), 3(2), 59-66 CODEN: INOLEG;ISSN: 1192-5612, March 1995, XP000575900 WULFING, CHRISTOPH ET AL: "Soluble T - cell receptor fragments. Guidance of folding and assembly"	1-21

International application No.

CT/US 95/16937

Box I	Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)
This inte	ernational search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:
1. X	Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:
<u> </u> -	Remark: Although claims 22,23 and 29-38 are directed to a method of treat-
	ment of the human/animal body the search has been carried out and based on the alleged effects of the compound.
2.	Claims Nos.: because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
	Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).
Box II	Observations where unity of invention is tacking (Continuation of item 2 of first sheet)
This Inter	rnational Searching Authority found multiple inventions in this international application, as follows:
1. 🔲 🔏	As all required additional search fees were timely paid by the applicant, this international search report covers all earchable claims.
2	As all searchable claims could be searches without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3 A	as only some of the required additional search fees were timely paid by the applicant, this international search report overs only those claims for which fees were paid, specifically claims Nos.:
4. N	o required additional search fees were timely paid by the applicant. Consequently, this international search report is stricted to the invention first mentioned in the claims; it is covered by claims Nos.:
Remark on	Protest The additional search fees were accompanied by the applicant's protest.
	No protest accompanied the payment of additional search fees.

iformation on patent family members

Inter onal Application No PCI/US 95/16937

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
WO-A-9412648	09-06-94	FR-A- AU-B- CA-A- EP-A- JP-T-	2698880 5566894 2128705 0624201 7506495	10-06-94 22-06-94 09-06-94 17-11-94 20-07-95
WO-A-9201715	06-02-92	NONE		
WO-A-9312814	08-07-93	AU-B- CA-A- EP-A- JP-T-	3418893 2126686 0623025 7506563	28-07-93 08-07-93 09-11-94 20-07-95